Zimlovisertib

About Zimlovisertib (CAS 1817626-54-2)

Zimlovisertib is a selective small-molecule kinase inhibitor developed for research into innate immune signaling and inflammatory disease biology. In scientific catalogs and pharmacology references, it is also identified as PF-06650833, pf 06650833, CAS 1817626-54-2, and 1817626-54-2. This compound is especially relevant in studies where interleukin-1 receptor-associated kinase 4 activity must be modulated with a defined and well-characterized tool molecule. Pharmacology references describe PF-06650833 irak4 inhibitor activity as potent, selective, and reversible, while also noting that the approved international nonproprietary name zimlovisertib refers to the same chemical entity. Zimlovisertib's molecular formula is C18H20FN3O4, and Zimlovisertib chemical structure is identical to that of PF-06650833, making both identifiers important for catalog matching, analytical verification, and cross-platform sourcing.

Application of Zimlovisertib

In research settings, zimlovisertib is used in immunology, inflammation biology, kinase signaling, and translational pharmacology. Its main application lies in projects focused on IRAK4-dependent pathways that connect Toll-like receptor and interleukin-1 receptor signaling with downstream inflammatory responses. Because IRAK4 plays a central role in cytokine-driven signaling cascades, this molecule is useful in studies of rheumatoid arthritis, systemic lupus erythematosus, and broader immune-mediated disorders. Supplier summaries and literature references also position Pfizer Zimlovisertib as a clinically advanced reference compound, which adds value for teams comparing early-stage tool molecules with more mature development candidates.

In Vitro

In vitro, PF-06650833 has shown the ability to suppress inflammatory responses in primary human cells exposed to physiologically relevant stimuli derived from rheumatoid arthritis and systemic lupus erythematosus settings. This makes the molecule especially valuable in assay systems designed to connect target engagement with changes in cytokine output and pathway activation. In pharmacology databases, zimlovisertib is described as a potent and selective IRAK4 inhibitor with a profile suggesting oral bioavailability, which strengthens its value in studies that require both mechanistic precision and translational relevance. For discovery teams, these features make it suitable for pathway validation, comparative inhibitor profiling, and immune-response modeling.

In Vivo

In vivo, PF-06650833 has been reported to block inflammation in preclinical models of rheumatologic disease and has also been studied in humans enrolled in randomized clinical trials. This link between controlled in vitro findings and measurable activity in living systems is one of the key reasons the compound remains useful in translational research. It provides a clearer bridge between biochemical inhibition of IRAK4 and downstream physiological effects in disease-relevant inflammatory settings, which is often essential when selecting a reference molecule for advanced study design.

Biochemical and Physiological Actions

Biochemically, zimlovisertib acts as a reversible IRAK4 inhibitor and interrupts signaling downstream of receptors that rely on this kinase to propagate inflammatory cascades. Physiologically, this can reduce cytokine-driven immune activation and modulate disease-associated inflammatory responses. Literature and pharmacology sources consistently describe the compound as potent and selective, which is important for researchers who need cleaner mechanistic readouts and less uncertainty from off-target effects. The fact that Zimlovisertib chemical structure is explicitly linked to PF-06650833 in pharmacology databases also supports consistent interpretation across research and sourcing environments.

Features and Benefits of Zimlovisertib

• Defined identifiers, including CAS 1817626-54-2, PF-06650833, and searchable Zimlovisertib molecular formula data
• Potent and selective IRAK4 inhibition relevant for inflammation, immunology, and translational pharmacology studies
• Strong fit for teams comparing pf 06650833 with other kinase-directed compounds in validated workflows

For EBC-412094, zimlovisertib offers a combination of structural clarity, pathway relevance, and research-grade translational value that supports confident use in modern IRAK4-focused programs.